Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Study further supports the expansion of clinical trials of MYCO-001 for the treatment of PTSD among the Veteran population DENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders…

Source